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In vivo gene transfer to kidney by lentiviral vector. and viral vectors [2]. Adenoviral vectors [3–5], as well
Background. The growing understanding of the molecular as synthetic DNA transduction methods [6–9], result in
basis of renal diseases makes the development of gene therapy transient expression of the transgene. Murine retrovi-for kidney disorders a potential treatment alternative. Work
ruses transduce tubular epithelial cells only following aaimed at determining the feasibility and the efficiency of gene
regenerative response induced by nephrotoxic injurytransfer to the kidney using different viral and nonviral trans-
duction systems is a necessary component to understanding the [10]. The dependence of murine or avian retroviruses
full potential. Lentiviral vectors have been shown to transduce on cell proliferation for stable integration may limit their
stably different tissues and cell types that are refractory to other application in renal gene therapy because most of thegene transfer approaches. To date, the potential of lentiviral
cells in the kidney are postmitotic. Recombinant adeno-vectors to transfer genes in kidney has not been investigated.
associated virus (AAV) vectors result in stable expres-The scope of this work was to analyze the efficiencies of in
vivo transduction of kidney by a lentiviral vector. sion of transgene following renal parenchymal injection
Methods. A pseudotyped lentiviral vector carrying the gene [11]. Nevertheless, some limitations are inherent to re-
for the enhanced green fluorescent protein (EGFP) was deliv- combinant AAV vectors such as the loss of site-specificered into one kidney of experimental mice by retrograde infu-
integration characteristic of the wild-type AAV and thesion through the ureter. The presence of the virus and the ex-
relatively small cloning capacity. Therefore, the furtherpression of the reporter protein were monitored over time.
Results. Both viral DNA and EGFP expression were mea- analysis of gene transfer methods and vector systems is
surable in the kidney infused with the lentiviral vector but not essential for the improvement of renal gene therapy.
in the contralateral kidney. Protein expression was detected Gene delivery systems based on lentiviral vectors haveby immunostaining, as EGFP fluorescence was masked by the
been shown to transduce a wide variety of organs andhigh background fluorescence of the kidney. Expression of
tissues, including the brain [12–14], liver [15], hematopoi-EGFP persisted for the entire two-month duration of the exper-
iments. etic cells [16], and myocytes [17] either in vitro or in
Conclusions. Lentiviral vectors can effectively deliver exog- vivo. However, the transduction of kidney using lenti-
enous genes to the kidney in vivo, resulting in persistent expres-
viral vectors has not yet been examined. Lentiviral vec-sion of the introduced gene.
tors may offer unique advantages as compared with other
delivery systems in targeting kidney cells. They provide
persistent transduction through stable integration intoGene transfer into cells in solid organs is a fundamen-
the host genome of proliferating as well as nondividingtal goal and presents a major challenge for gene therapy.
and terminally differentiated cells (for example, adultThe identification of genes involved in renal diseases has
kidney cells). These are essential characteristics, as theelicited great interest in gene therapy as an attractive
correction of the diseased phenotype in many cases willpotential treatment for many genetic and metabolic dis-
require continuous expression of the transgene. More-orders that affect the kidney [1]. Unfortunately, the ana-
over, the recent developments in vector design [18, 19]tomical complexity of the kidney and the heterogeneity
and the establishment of stable packaging cell lines [20]of the cell types that contribute to the specialized func-
have significantly increased the safety and the ease oftion of the nephron make in vivo transduction of kidney
production of lentiviral vectors, respectively.a challenging task.
The aim of our studies was to determine whether len-To date, in vivo gene transduction of kidney cells has
tiviral vectors could transduce renal cells in vivo. We ex-been addressed using different gene transfer systems
plored the lentivirus-mediated delivery of a reporter gene,based on naked DNA, cationic lipid complexed-DNA,
enhanced green fluorescent protein (EGFP), in kidney
in vivo following intraureteral injection. We show that
Key words: lentivirus, gene transfer, gene therapy, kidney. both transgene DNA and transgene expression are de-
tectable in the lentiviral-transduced kidney for the entire 2002 by the International Society of Nephrology
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duration of the experiments. These results prove that scoring the number of positive cells expressing the EGFP
transgene detected by fluorescence microscopy.lentiviral vector can effectively deliver exogenous genes
in renal cells in vivo, resulting in persistent gene expres-
Retrograde ureteral infusionsion, and that they can be a valuable tool for the gene
All animal experiments were conducted according totherapy of kidney diseases.
the Institutional Animal Care and User Committee of
Mount Sinai School of Medicine. One-month-old FVB/N
METHODS mice were anesthetized with Avertin (2,2,2-tribromo-
Viral vector preparation ethanol in 2 mL 2-methyl-2-butanol, 375 g/kg intraperi-
toneally). The left kidney was exposed via a flank inci-To construct the pHRPGK, KS-PGK, a bluescript KS
sion and gently separated from the surrounding fat. Theplasmid (Stratagene, La Jolla, CA, USA) containing the
ureter was clamped distal to the infusion site, and the leftmurine phosphoglycerate kinase (PGK) promoter in the
uretero-pelvic junction was cannulated with a 30-gaugeEcoRI site was digested with BamHI, filled in with Kle-
needle under stereomicroscopic guidance. Approximatelynow polymerase, and self-ligated to generate a ClaI site.
one 5  108 TUs of lentiviral vector in 80 L of PBSThe ClaI-HindIII fragment containing the PGK promoter
were infused under gentle pressure to avoid renal pelvicwas inserted into the corresponding sites of pcD31/C2
distention and hematuria or leaking of the injected solu-derived from the insertion of a ClaI linker into the NruI
tion from the injection site. After five minutes, the cathe-site of the pcDNA3.1 plasmid (Invitrogen, Carlsbad, CA,
ter was removed, and urine flow was restored. The ab-USA). The PGK promoter with the adjacent 3 poly-
dominal muscles were then sutured, using absorbablelinker site was excised with ClaI and XhoI and inserted
suture material, and the skin was closed with surgicalinto the corresponding sites of pHR [21] (kindly pro-
staples. The animals were placed in individual cages, andvided by Dr. D. Trono) to generate the pHRPGK vec-
their recovery was monitored.tor. The EGFP gene from the pEGFP1 (Clontech, Palo
Alto, CA, USA) digested with BamHI and NotI was Tissue processing
ligated into the corresponding sites of pHRPGK to gen-
After one or two months, the animals were anesthe-erate pHRPGK/EGFP. Supernatants containing the in-
tized with Avertin and killed by decapitation. Kidney tis-fectious lentiviral vectors pseudotyped with the vesicular
sue obtained from experimental animals was bisected
stomatitis virus glycoprotein (VSV-G) were produced
and fixed in 4% paraformaldehyde in PBS for four hours
by transient transfection of 293T cells using pHRPGK/
at 4C. One half of each fixed kidney was embedded in
EGFP, pCMVR8.2 containing all of the transcomple- paraffin and 5 m-thick sections were cut. Sections were
menting viral proteins except env, and pMD.G plasmids, then dewaxed and taken through a series of graded alco-
which codifies for the VSV-G protein [21] in a 4:3:1 ratio hol rehydration steps. The other halves of fixed kidney
and Lipofectamine 2000 lipid transfection system (Life tissue were washed in PBS, transferred into 15% sucrose
Technologies, Gaithersburg, MD, USA) according to for 12 hours, and snap frozen using Gentle Jane Snap-
manufacturer’s instruction. Cells were seeded at 8  106 Freezing system (Instrumedics Inc., Hackensack, NJ,
in T75 flasks in complete Dulbecco’s modified Eagle’s USA), and 5 m-thick sections were cut using sliding
medium (DMEM supplemented with 4.5 g/L d-glucose, microtome cryostat. The sections were mounted using
10% fetal bovine serum, 2 mmol/L glutamine, 100 U/mL Vectashield mounting medium (Vector Laboratories, Bur-
penicillin, and 100 mg/mL streptomycin) 24 hours before lingame, CA, USA) and used for fluorescence micros-
the transfection. A total of 20 g of plasmid DNA was copy. To reduce the background fluorescence, some of
used per flask. Medium was replaced after 16 hours fol- the frozen sections were immersed for 45 minutes
lowing transfection with complete medium supple- in a solution of 0.1% NaBH4 in PBS in low light [22].
mented with 4 mmol/L sodium butyrate (Sigma, St. The sections were then rinsed three times in PBS and
Louis, MO, USA). Supernatants were harvested 24 and mounted in Vectashield mounting medium (Vector Lab-
48 hours later and filtered though a 0.45 m pore-size oratories) before fluorescence microscopy analysis.
filter, and viral particles were concentrated by centrifuga-
Immunohistochemistrytion for five hours at 15,000 rpm. Viral pellets were resus-
pended in 1% of the starting volume of medium in sterile Immunostaining was performed on paraffin sections
phosphate-buffered saline (PBS) and titer determined to detect EGFP. For each specimen, multiple sections
as transduction units (TUs). Briefly, serial dilutions of were first incubated in a blocking solution consisting of
each supernatant were used to infect 104 HeLa-Tat cells PBS containing 10% normal goat serum for 40 minutes at
per well in 24-well plates in the presence of complete room temperature and then with anti-EGFP polyclonal
medium supplemented with 10g/mL Polybrene (Sigma). rabbit antibodies (Clontech) at 1:50 dilution. Goat anti-
rabbit biotinylated secondary antibodies diluted 1:200 inThe TU was determined 48 hours following infection by
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Fig. 1. Fluorescence microscopy of untreated
(c and f ) and HRPGK/EGFP-infused kidney
(a, b, d, and e) at one month. The corticomed-
ullary junction (a–c) and the cortex areas (d–f)
are shown. Sections in b and e, from virus-
treated kidney, were treated with sodium bor-
ohydride as described in the Methods section.
The treatment resulted in a general decrease
of the autofluorescence without, however, im-
proving the specific signal.
PBS and avidin-biotin-horseradish-peroxidase were used
for detection using the ABS kit (Vector Laboratories) ac-
cording to the manufacturer’s instruction. Sections were
developed in 3-amino-9-ethylcarbazole (AEC) solution
(Vector Laboratories). For a negative control, immune
serum was replaced by PBS. The tissues were counter-
stained with hematoxylin (Vector Laboratories) for eas-
ier visualization and mounted using Aqua Poly/Mount
medium (Polysciences, Inc., Warrington, PA, USA) for
microscopic analysis.
DNA extraction and polymerase chain reaction
Total DNA from fixed frozen kidney was extracted us-
ing the QIAamp tissue kit (Qiagen, Valencia, CA, USA)
according to manufacturer’s instructions. Equal amounts
of DNA from each sample were used in the polymerase
chain reaction (PCR) amplification. For the amplifica-
Fig. 2. Detection of EGFP transgene DNA in lentiviral transduced
tion of EGFP, the PCR reactions were performed in the kidneys. Kidneys were collected one month (lanes 3 and 4) or two
months (lanes 5 and 6) after viral infusion. Total DNA was extractedfollowing PCR mixture: PCR buffer 2.5 mmol/L MgCl2,
from kidneys infused with HRPGK/EGFP (lanes 3 and 5) and contra-200 mol/L dNTPs, 5 U Taq, 100 ng/L of the following lateral kidneys (lanes 4 and 6) and subjected to PCR amplification for
primers: primers 5E, 5-TGACCCTGAAGTTCATCTG EGFP or G3PDH. Lanes 1 and 2 show the reaction products of the
negative control, in which the template DNA was omitted, and theCACCACCGGCA-3, and 3E, 5-CGAGCTGCACGC
positive control, in which a plasmid containing the EGFP gene wasTGCCGTCCTCGATGTTGT-3. PCR was performed used as template, respectively. MW, DNA molecular weight markers.
for 45 cycles at 94C for 30 seconds and at 72C for 1
minute. A final elongation step at 72C for two minutes
was added. The amplification of the cellular gene G3PDH
was carried out in the same PCR reaction mixture for vector HRPGK/EGFP. In this vector, the expression of
20 cycles at 94C for 1 minute, 58C for 30 seconds, and the EGFP gene is driven by the constitutive murine PGK
72C for 45 seconds using the primers: G3PDH/forward, promoter.
5-ACCACAGTCCATGCCATCAC-3, and G3PDH/ Animals were sacrificed one or two months following
reverse, 5-TCCACCACCCTGTTGCTGTA-3. The am- viral injection, and both injected and contralateral con-
plified products were separated by electrophoresis on trol kidneys were harvested and snap frozen to analyze
1.5% agarose gel and visualized by ethidium bromide EGFP expression. Each kidney was cut transversally in
staining.
two halves that were used either for microtome dissec-
tion or for PCR analysis. The detection of EGFP by
RESULTS fluorescence microscopy proved particularly difficult in
the kidney because of the very high background fluores-To determine whether lentiviral vectors could trans-
cence of kidney sections, particularly in the cortex orduce renal cells in vivo, retrograde ureter injection was
possibly because of the relatively weak intensity of theperformed on one-month-old FVB/N mice to infuse ei-
ther control PBS or five 10  107 TUs of the lentiviral expressed EGFP (Fig. 1). Alternative methods to reduce
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Fig. 3. Expression of EGFP in lentiviral trans-
duced kidneys. Sections were prepared from
kidneys collected one month (a and b) or two
months (c–e) following retrograde lentiviral
infusion or PBS infusion. The immunodetec-
tion for EGFP showed clear positive staining
in the corticomedullary junction of the
HRPGK/EGFP-infused kidneys (b and d).
Control contralateral kidneys (a and c) and a
PBS-injected kidney (e) were used as control
and showed no specific staining.
spontaneous fluorescence, such as sodium borohydride Alport’s syndrome, renal tubular acidosis, and polycystic
kidney disease or to prevent localized renal inflamma-treatment [22], were not effective.
tory processes will depend on effectively delivering theIn order to assess whether viral infection had occurred,
therapeutic gene to the kidney. Here we have reportedthe presence of EGFP gene was analyzed by PCR ampli-
that lentiviral vectors successfully transduced kidneyfication on total DNA extracted from the frozen half of
cells in vivo following retrograde infusion through theeach kidney. Equal amounts of total DNA were used in
ureter and resulted in the persistent expression of thethe amplification reaction. A 410 bp band correspond-
reporter transgene, EGFP, up to the two-month durationing to the amplified EGFP DNA was detectable in the
of the experiments.kidneys both after one month and two months following
Despite the initial difficulties we encountered in di-the viral infusion (Fig. 2). No amplification product was
rectly analyzing EGFP expression through fluorescencedetected in the kidneys of animals injected with PBS
microscopy, the detection of retrotranscribed viral DNA,alone or in the contralateral kidneys of virus-infused ani-
measured by PCR amplification of the transgene, indi-mals. The G3PDH gene was readily amplifiable in all
cated that the lentiviral vector entered the renal cells.of the samples confirming the integrity of all the DNA
Transduction was confirmed by the immunohistologicalspecimens.
detection of the expressed EGFP. The expression of thePossible explanations for the lack of easily detectable
transgene delivered by the lentivirus was predominantlyEGFP fluorescence included promoter inactivation or
detected in the corticomedullary junction and appearedthe masking of EGFP by the high background fluores-
to involve mostly proximal straight tubules. The localiza-cence. To address these hypotheses, we analyzed EGFP
tion of EGFP expression within the bright autofluores-expression by immunohistochemistry using a specific
cent cortical boundary may in part explain the difficultyanti-EGFP polyclonal rabbit antibody. The immuno-
in detecting the reporter by fluorescence. This distribu-detection showed EGFP-specific staining in virus-infused
tion differs from that previously observed in rats withkidneys but not in control contralateral kidneys or in the
adenoviral vectors administered through the same routekidney of animals infused with PBS (Fig. 3). In the kidney
[3]. In fact, adenovirus-delivered transgenes were ex-infused with HRPGK/EGFP, the signal was distributed
pressed predominantly in the papilla and medulla follow-along the corticomedullary junction with prominent lo-
ing retrograde infusion, whereas expression in proximalcalization in the proximal straight tubules. EGFP expres-
tubules in the cortical area resulted from perfusion viasion was still readily detectable up to the termination of
the renal artery [23]. However, similarly to lentivirus,the experiments, two months after lentivirus infusion.
liposome complexed-DNA infused retrograde via theThese data also indicated that the PGK promoter was ac-
ureter targeted the transgene primarily to the outer me-tive during the duration of the experiments and suggested
dulla and cortex [24]. The reasons for these differencesthat EGFP fluorescence may not be a reliable readout for
remain to be elucidated, and more comparative experi-the determination of EGFP expression in kidney.
ments will be needed to determine whether the differ-
ential distribution depends on the delivery system, the
DISCUSSION promoter used, the physical parameters of delivery, tech-
The development of an efficient gene transfer ap- nical procedures, or animal models. The possibility of
selectively accessing different segments of the nephron,proach to address many inherited renal disorders such as
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